SCHEMBL20002542

SCHEMBL20002542

CS(=O)(=O)N1CCC2(CC1)CC(O)(c1cc(Cl)cc3cn[nH]c13)C2

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
CYP3A4 P08684 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
USP2 O75604 2/20 0.37
CYP2C9 P11712 6/20 0.36
CYP2C19 P33261 4/20 0.36
HIF1A Q16665 2/20 0.36
CYP2D6 P10635 6/20 0.34
CYP1A2 P05177 4/20 0.34
ACACB O00763 6/20 0.34
ALOX15 P16050 2/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20002263 0.91 CYP11B2 (0.39) ALDH1A1CYP3A4HPGDHSD17B10USP2
SCHEMBL20042247 0.89 ACACB (0.33) ACACBTDO2
SCHEMBL20042253 0.88 TDO2 (0.34) ACACBTDO2
SCHEMBL20002260 0.84 TDO2 (0.34) ACACBSMN1; SMN2IDO1TDO2MEN1
SCHEMBL20001913 0.84 TDO2 (0.38) TDO2
SCHEMBL20001770 0.82 CYP2C9 (0.36) ALDH1A1CYP3A4HPGDHSD17B10USP2
SCHEMBL20002452 0.82 ACACB (0.37) ACACB
SCHEMBL20002073 0.81 TDO2 (0.39) TDO2
SCHEMBL19995846 0.81 TDO2 (0.39) TDO2
SCHEMBL22584292 0.81 PSEN1 (0.37) SMN1; SMN2TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099939-A1 COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2018-04-12 US disclosed
US-20180099939-A1 COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2018-04-12 US disclosed
WO-2018057973-A1 COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099939-A1 COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR IDO1, TDO2, IDO2 ALDH1A1 719/4885CYP3A4 140/4885HPGD 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.